Targeting Novel Pain Management Solutions
Scintilla Pharmaceuticals, Inc. is a majority-owned subsidiary of Sorrento Therapeutics, Inc. We are a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.
We believe that the therapeutic advantages of our products and technology will improve product efficacy and safety making a substantial improvement in the treatment of pain.
In the United States, Scintilla plans to develop and commercialize product candidates, either through its own efforts or in conjunction with partners. Outside of the United States, we anticipate commercializing these products through select regional partnerships worldwide.
- Two Product Candidates with Blockbuster Potential Poised to Replace Current Standard of Care
- Established Reimbursement Access
- Strong Proprietary Platform with High Barriers to Entry
- Worldwide Commercial Rights to All Product Candidates
- Large, Established, yet Underserved Target Markets
- Innovative, Non-opioid Pain Management Portfolio